Hualan Biological Engineering Valuation
Is 2007 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 2007 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: 002007 (CN¥20.76) wird unter unserer Schätzung des Fair Value (CN¥20.87) gehandelt.
Deutlich unter dem Marktwert: 002007 unter dem beizulegenden Zeitwert gehandelt wird, jedoch nicht um einen signifikanten Betrag.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2007?
Other financial metrics that can be useful for relative valuation.
| What is 2007's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥35.55b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.6x |
| Enterprise Value/EBITDA | 17.2x |
| PEG Ratio | 1.6x |
Price to Earnings Ratio vs Peers
How does 2007's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 64.3x | ||
600161 Beijing Tiantan Biological Products | 40.1x | 17.9% | CN¥44.5b |
300601 Shenzhen Kangtai Biological Products | 68.7x | 47.1% | CN¥24.8b |
688276 Changchun BCHT Biotechnology | 36.7x | 27.5% | CN¥18.4b |
603087 Gan & Lee Pharmaceuticals | 111.5x | 68.1% | CN¥26.9b |
002007 Hualan Biological Engineering | 24x | 15.1% | CN¥35.6b |
Price-To-Earnings gegen Gleichaltrige: 002007 ist ein guter Wert, wenn man sein Price-To-Earnings Verhältnis (34.2x) mit dem Durchschnitt der anderen Unternehmen (89.3x) vergleicht.
Price to Earnings Ratio vs Industry
How does 2007's PE Ratio compare vs other companies in the CN Biotechs Industry?
Price-To-Earnings gegen Industrie: 002007 ist aufgrund seines Price-To-Earnings Verhältnisses (34.2x) im Vergleich zum CN Biotechs Branchendurchschnitt (39.8x) ein guter Wert.
Price to Earnings Ratio vs Fair Ratio
What is 2007's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 24x |
| Fair PE Ratio | 26.3x |
PM vs. Fair Ratio: 002007 ist ein guter Wert auf der Grundlage des Verhältnisses Price-To-Earnings (24.9x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Earnings (26.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CN¥19.44 | CN¥25.58 +31.6% | 13.4% | CN¥32.00 | CN¥19.00 | n/a | 8 |
| Mar ’25 | CN¥19.81 | CN¥25.43 +28.4% | 13.6% | CN¥30.00 | CN¥19.00 | n/a | 8 |
| Feb ’25 | CN¥17.76 | CN¥26.26 +47.9% | 12.8% | CN¥30.00 | CN¥19.00 | n/a | 7 |
| Jan ’25 | CN¥22.13 | CN¥25.89 +17.0% | 13.5% | CN¥30.00 | CN¥19.00 | n/a | 6 |
| Dec ’24 | CN¥24.44 | CN¥25.89 +5.9% | 13.5% | CN¥30.00 | CN¥19.00 | n/a | 6 |
| Nov ’24 | CN¥23.57 | CN¥26.35 +11.8% | 14.0% | CN¥31.13 | CN¥19.00 | n/a | 7 |
| Oct ’24 | CN¥22.20 | CN¥26.78 +20.6% | 15.7% | CN¥33.00 | CN¥19.00 | n/a | 7 |
| Sep ’24 | CN¥21.33 | CN¥26.97 +26.4% | 18.0% | CN¥33.00 | CN¥19.00 | n/a | 6 |
| Aug ’24 | CN¥22.89 | CN¥27.30 +19.3% | 17.7% | CN¥33.00 | CN¥19.00 | n/a | 6 |
| Jul ’24 | CN¥22.41 | CN¥27.30 +21.8% | 17.7% | CN¥33.00 | CN¥19.00 | n/a | 6 |
| Jun ’24 | CN¥21.99 | CN¥27.47 +24.9% | 16.6% | CN¥33.00 | CN¥20.00 | n/a | 6 |
| May ’24 | CN¥23.28 | CN¥27.47 +18.0% | 16.6% | CN¥33.00 | CN¥20.00 | n/a | 6 |
| Apr ’24 | CN¥21.83 | CN¥26.38 +20.8% | 16.6% | CN¥32.00 | CN¥20.00 | CN¥19.91 | 5 |
| Mar ’24 | CN¥22.33 | CN¥26.17 +17.2% | 18.6% | CN¥32.00 | CN¥20.00 | CN¥19.81 | 4 |
| Feb ’24 | CN¥22.43 | CN¥26.17 +16.7% | 18.6% | CN¥32.00 | CN¥20.00 | CN¥17.76 | 4 |
| Jan ’24 | CN¥22.63 | CN¥23.42 +3.5% | 16.9% | CN¥29.69 | CN¥20.00 | CN¥22.13 | 4 |
| Dec ’23 | CN¥20.51 | CN¥23.42 +14.2% | 16.9% | CN¥29.69 | CN¥20.00 | CN¥24.44 | 4 |
| Nov ’23 | CN¥17.64 | CN¥25.19 +42.8% | 13.1% | CN¥29.69 | CN¥20.60 | CN¥23.57 | 5 |
| Oct ’23 | CN¥18.16 | CN¥25.39 +39.8% | 12.8% | CN¥29.69 | CN¥20.60 | CN¥22.20 | 5 |
| Sep ’23 | CN¥20.46 | CN¥25.39 +24.1% | 12.8% | CN¥29.69 | CN¥20.60 | CN¥21.33 | 5 |
| Aug ’23 | CN¥19.90 | CN¥25.67 +29.0% | 12.2% | CN¥29.69 | CN¥21.00 | CN¥22.89 | 5 |
| Jul ’23 | CN¥23.15 | CN¥25.27 +9.2% | 14.9% | CN¥29.69 | CN¥19.00 | CN¥22.41 | 5 |
| Jun ’23 | CN¥18.50 | CN¥27.73 +49.9% | 23.4% | CN¥40.00 | CN¥19.00 | CN¥21.99 | 6 |
| May ’23 | CN¥16.69 | CN¥32.08 +92.2% | 38.7% | CN¥55.82 | CN¥19.00 | CN¥23.28 | 6 |
| Apr ’23 | CN¥20.21 | CN¥36.14 +78.8% | 29.2% | CN¥55.82 | CN¥23.50 | CN¥21.83 | 6 |
Analysten-Prognose: Das Kursziel liegt mehr als 20% über dem aktuellen Aktienkurs, und die Analysten liegen in einem statistisch sicheren Bereich der Übereinstimmung.